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Abstract
Background: Lack of treatment initiation or intensification might explain why some patients with
type 2 diabetes do not reach target goals. The objective is to assess trends in risk factor treatment,
and identify determinants for medication adjustments in patients with uncontrolled hypertension
and/or hyperlipidemia.
Methods: We conducted a cohort study using data from the Zwolle Outpatient Diabetes project
Integrated Available Care (ZODIAC)-study in The Netherlands. Management of hypertension and
hyperlipidemia was assessed yearly from 1998–2004 by measuring the percentage of patients
receiving a treatment initiation or intensification among all patients with elevated risk factor levels.
Generalized estimating equation analyses were performed.
Results: During the study period, the percentage of patients with an elevated total cholesterol/
high-density lipoproteins ratio (>6) decreased considerably (from 29% to 4%) whereas the
percentage of hypertensive patients decreased only slightly (≥ 150/85 mmHg; from 58% to 51%).
Initiation of lipid-lowering therapy and intensification of antihypertensive therapy was higher in
more recent years. However, still two-third of patients with insufficiently controlled blood
pressure in 2003 did not receive an initiation or intensification of antihypertensive treatment in the
following year. Treatment changes were mainly determined by elevated levels of the corresponding
risk factor. We did not observe increased initiation rates for lipid-lowering therapy in patients with
both hypertension and hyperlipidemia.
Conclusion:  Hypertension and hyperlipidemia management in type 2 diabetes patients has
improved in the past decade but further improvement is possible. Greater effort is needed to
stimulate medication adjustments in patients with insufficiently controlled hypertension and
combined risk factors.
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Background
The increased incidence of cardiovascular disease (CVD)
among patients with type 2 diabetes has led to increased
recognition of hypertension and hyperlipidemia as
important targets of therapy in addition to hyperglycemia
[1,2]. Clinical trials in patients with type 2 diabetes con-
vincingly demonstrated that cholesterol reduction and
tight blood pressure control reduce the risk of major car-
diovascular events [3-5]. Diabetes guidelines therefore
advocate an intensified treatment approach aiming at all
risk factors for the primary prevention of CVD [6-9].
It has been shown that although increasing numbers of
diabetes mellitus patients are nowadays tested for relevant
risk factors, much smaller percentages reach target goals
[10-12]. These findings might be explained by low rates of
medication initiation and dose adjustment in patients
with elevated risk factor levels [11,13,14]. In addition,
there are doubts that general practitioners have suffi-
ciently implemented a multiple risk factor approach in
routine practice [15,16]. This could also contribute to
patients being undertreated. Observational studies so far,
however, have focussed mainly on the influence of single
elevated risk factors on treatment modifications
[11,13,14]. Moreover, these studies have only looked at
changes in drug regimes over short periods of time, not
allowing for the assessment of trends. It is therefore not
clear whether treatment of multiple risk factors in patients
with diabetes has intensified over the past years.
The objectives of the present study were (1) to examine
trends in initiation and intensification of lipid-lowering
and antihypertensive drug therapy among type 2 diabetes
patients, and (2) to analyze factors associated with these
drug regime changes, in particular looking at combined
risk factors.
Methods
Setting
This study was conducted as part of an ongoing longitudi-
nal study, the Zwolle Outpatient Diabetes project Inte-
grated Available Care (ZODIAC)-study in The
Netherlands. The ZODIAC-study is a shared-care project
for type 2 diabetes within the primary setting that started
in 1998. Details about this project have been published
previously [17]. In brief, general practitioners (GPs) are
supported by diabetes specialist nurses (DSNs) for con-
ducting the annual control of their type 2 diabetes
patients. The GPs kept full responsibility for the care of
these patients and remained responsible for drug prescrib-
ing and check-ups that should take place every three
months. The number of participating GPs ranged from 32
in 1998 to 46 in 2004.
Study subjects
The study population represents a dynamic cohort of type
2 diabetes patients who had at least two visits in consecu-
tive years for their annual control to a DSN between 1998
and 2004. During this period, all patients with known
and newly diagnosed type 2 diabetes were included when
they met the following criteria in the judgement of their
GP: (1) treated exclusively in primary care; (2) no termi-
nal illness, and (3) no severe deficits in memory and
understanding.
Measurements
The annual visit to the DSN included registration of the
following data: (1) medication use (general and diabetes
medication) and medical history as provided by the GP
and checked with the patient; (2) height, weight, blood
pressure measured at the visit; and (3) laboratory values
that had been measured before the visit. The laboratory
measurements were glycosylated haemoglobin (HbA1c),
total cholesterol (TC), high-density lipoproteins (HDL)
and low-density lipoproteins (LDL). All laboratory meas-
urements were performed in a central laboratory. Medical
history included year of diabetes onset and history of
myocardial infarction and/or angina pectoris. Body mass
index was calculated from weight and length (kg/m2). The
TC/HDL ratio was calculated from total cholesterol and
HDL cholesterol.
Guideline recommendations
During the study period, the Dutch General Practitioners'
guidelines recommended a combined assessment of
blood pressure and lipid levels to guide treatment to
patients at high risk for CVD [6,18]. Lipid-lowering ther-
apy should be targeted to patients at greatest risk for CVD:
i.e. patients with pre-existing CVD, patients with a (sus-
pected) hereditary lipid disorder or patients with an esti-
mated 10-year coronary heart disease risk larger than 25%
as based on the Framingham risk score [6,18]. To elimi-
nate the need for GPs to calculate risk scores, the guide-
lines incorporate colour-coded risk tables to guide
management for primary prevention based on a person's
age, sex, smoking status, blood pressure, and TC/HDL
ratio. From these tables, it can be derived that the presence
of hypertension determines the need for lipid-lowering
treatment in non-smoking patients with a TC/HDL ratio
of 5–7, and in smoking patients with a TC/HDL ratio of
4–6. The guideline, however, also provides two simplified
recommendations for the primary prevention: men aged
50–70 years and women aged 50–75 years should receive
lipid-lowering therapy when their TC/HDL ratio is higher
than 6 for non-smoking patients and when their TC/HDL
ratio is higher than 5 for smoking patients [6]. Further-
more, patients with hypertension (defined as a systolic
blood pressure (SBP) ≥ 150 mmHg or a diastolic bloodCardiovascular Diabetology 2007, 6:25 http://www.cardiab.com/content/6/1/25
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pressure (DBP) ≥ 85 mmHg) should be treated with anti-
hypertensive drugs [6,19].
Changes in drug therapy
Using the prescribing information from reports of annual
controls by the DSNs, we determined for each patient in
each year whether the patient had received an initiation or
intensification of drug therapy. Drug therapy was consid-
ered to have been intensified if the dose was increased or
an additional drug class was added. A switch to another
drug class without continuation of the original medica-
tion was not considered as an intensification of therapy,
because patients could have been switched due to side
effects. Trends in drug regime changes were studied over
the period 1999–2004 to determine whether the GPs
changed prescribing rates for lipid-lowering and antihy-
pertensive drug therapy. Furthermore, we examined to
what extent such changes in drug treatment were deter-
mined by risk factor levels measured prior to these
changes.
Statistical analyses
Descriptive analyses characterize the population of type 2
diabetes patients over time, and show the frequencies of
drug regime initiations and intensifications in patients
with elevated risk factor levels. To identify determinants
for initiation and intensification of lipid-lowering and
antihypertensive drug therapy, generalized estimating
equation analyses were performed using STATA 8. With
generalized estimating equation analysis, the relation
between longitudinally measured variables can be studied
correcting for within person correlations caused by the
repeated measurements for one subject. Models were con-
structed for the changes in antihypertensive treatment and
changes in lipid-lowering treatment, and for initiation
and intensification separately. We assessed the influence
of the following factors: age, gender, SBP, DBP, TC/HDL
ratio and TC preceding a possible treatment change. Fac-
tors that contributed significantly (p < 0.05) to the model
were maintained in the final model (forward stepwise
regression). To test a possible combined effect of blood
pressure and lipid levels, an interaction term of SBP with
TC/HDL ratio was included in the models. We adjusted
for HbA1c, diabetes duration, history of myocardial inf-
arction and/or angina pectoris, body mass index, and year
of screening. Because initiation of lipid-lowering treat-
ment during our study period was recommended in men
younger than 70 years and women younger than 75 years,
we repeated analyses for lipid-lowering therapy including
only these patients. Results are presented as odds ratios
(OR) with corresponding confidence intervals (CI).
Results
Characteristics of the study cohort
The study population ranged from 946 to 1485 type 2 dia-
betes patients over the 6-year period from 1998 to 2003.
The mean age changed slightly from 68 years in 1998 to
67 years in 2003. Women represented the majority (on
average 57%) of the study population (Table 1).
The median duration of diabetes was 5 years and
remained reasonably stable over the years. Overall, 65%
of the patients was treated with oral hypoglycaemic drugs
only, and 15% received a combination of oral hypogly-
caemic drugs and insulin or insulin alone. We observed an
increase in the use of lipid-lowering drug treatments
(from 12% to 34%) and antihypertensive drug treatments
(from 48% to 69%) and substantial decreases in mean
HbA1c, TC/HDL ratio, and systolic blood pressure values
between 1998 and 2003 (Table 1).
Management of hyperlipidemia
During the study period, the percentage of patients with
an elevated TC/HDL ratio (>6) decreased considerably
from 29% (273/939) to 4% (59/1471) (Figure 1). In
1998, 9% (25/273) of these insufficiently controlled
patients were already on lipid-lowering drug therapy, and
11% (29/273) started treatment in the following year. By
2003, these percentages had increased to 25% (15/59) on
drug therapy, and another 26% (15/58) starting treatment
in the subsequent year. Almost no dose increase or addi-
tion of a drug class occurred over the years (Figure 1).
In multivariable analyses, TC/HDL ratio, SBP, age, history
of myocardial infarction and/or angina pectoris, and year
of screening were predictors of subsequent initiation of
Trends in percentages of patients with elevated TC/HDL val- ues and subsequent treatment modifications (1998–2004) Figure 1
Trends in percentages of patients with elevated TC/
HDL values and subsequent treatment modifications 
(1998–2004). TC, total cholesterol; HDL, high-density lipo-
protein.
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lipid-lowering therapy, while gender was not found to be
associated with treatment initiation (Table 2). There was
no significant interaction between TC/HDL values and
SBP levels, suggesting that the association between TC/
HDL ratio and subsequent initiation of lipid-lowering
therapy does not differ by SBP levels. Accordingly, we
observed no difference in the proportion of patients initi-
ated on lipid-lowering therapy who had elevated SBP lev-
els compared to normal SBP levels (Figure 2). Only 9% of
patients with SBP levels above 160 mmHg and TC/HDL
values between 5 and 6 were receiving a treatment initia-
tion, which was not higher than for patients with similar
TC/HDL values and SBP levels below 150 mmHg.
Intensification of lipid-lowering therapy was associated
with TC/HDL ratio and year of screening, but not with
SBP or other risk factors (Table 2). In subgroup analyses
of younger patients (men aged 70 years or younger and
women aged 75 years or younger), we found similar point
estimates for initiation and intensification of lipid-lower-
ing therapy, but age and SBP were not statistically signifi-
cant determinants anymore. Using total cholesterol as risk
factor instead of TC/HDL ratio yielded similar results
(data not shown).
Management of hypertension
The percentage of hypertensive patients (SBP ≥ 150
mmHg or DBP ≥ 85 mmHg) decreased from 58% (544/
930) in 1998 to 51% (754/1479) in 2003 (Figure 3). In
1998, 51% (279/544) of the patients not reaching blood
pressure targets were already on antihypertensive drug
therapy, and 10% (52/541) started treatment in the fol-
lowing year. By 2003, the percentage already treated had
increased to 72% (543/754), and another 8% of patients
started antihypertensive therapy (61/748). In the uncon-
trolled patients already on treatment, 19% (52/276)
received an intensification in 1999 and 35% (186/539) in
2004. Adding drugs was more common than increasing
the dose (Figure 3). Treatment intensifications were less
likely to occur in patients taking already two antihyperten-
sive drugs in 1998, and three or more drugs in 2003 (data
not shown). The percentage of uncontrolled patients
receiving no change in treatment decreased from 81% in
1998 to 67% in 2003 (black proportion of the bars in Fig-
ure 3).
In multivariable analyses, initiation of antihypertensive
therapy was positively related to preceding levels of SBP,
DBP, TC/HDL ratio, age, history of myocardial infarction
and/or angina pectoris, and year of screening, and nega-
tively related to HbA1c. Intensification of antihyperten-
Table 1: Characteristics of type 2 diabetes patients
1998
N = 946
1999
N = 1075
2000
N = 1248
2001
N = 1374
2002
N = 1295
2003
N = 1485
Patient characteristics
Age (years) 68 ± 11 68 ± 11 67 ± 11 67 ± 11 67 ± 11 67 ± 11
Female sex (%) 57% 58% 57% 57% 57% 55%
Duration of diabetes (years) 5 (2–10) 5 (2–10) 5 (2–10) 4 (2–9) 4 (2–9) 5 (2–9)
History of MI/AP 25% 22% 21% 19% 18% 18%
Body mass index (kg/m2) 29.0 ± 4.7 29.0 ± 4.7 29.4 ± 4.8 29.5 ± 4.8 29.5 ± 4.7 29.5 ± 4.8
HbA1c (% units) 7.5 ± 1.2 7.4 ± 1.2 7.3 ± 1.3 7.0 ± 1.2 7.0 ± 1.2 7.0 ± 1.2
TC/HDL ratio 5.3 ± 1.6 4.8 ± 1.3 4.5 ± 1.2 4.4 ± 1.2 4.1 ± 1.1 3.9 ± 1.1
Systolic blood pressure 
(mmHg)
155 ± 25 150 ± 23 150 ± 23 146 ± 20 145 ± 21 148 ± 21
Diastolic blood pressure 
(mmHg)
84 ± 11 82 ± 11 81 ± 11 80 ± 10 80 ± 10 84 ± 11
Number of glucose-lowering 
drugs
None 20% 17% 18% 20% 23% 20%
1 oral 43% 43% 41% 39% 36% 39%
≥ 2 oral 22% 25% 26% 26% 28% 26%
Insulin (with or without 
oral drugs)
15% 15% 15% 15% 13% 14%
Use of cardiovascular drugs
Lipid-lowering drugs 12% 15% 22% 27% 30% 34%
Antihypertensive drugs 48% 51% 57% 63% 66% 69%
ACE-inhibitors or ARBs 24% 26% 30% 36% 42% 45%
Antiplatelet drugs 22% 22% 23% 25% 25% 26%
Values are percentages, means ± standard deviations or median (interquartile range).
MI, myocardial infarction; AP, angina pectoris; HbA1c, haemoglobin A1c; TC, total cholesterol; HDL, high-density lipoprotein; ACE-inhibitors, 
angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers.Cardiovascular Diabetology 2007, 6:25 http://www.cardiab.com/content/6/1/25
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sive drug therapy was positively related to SBP, DBP, age,
and year of screening, but not with TC/HDL ratio or other
risk factors (Table 2).
Discussion
In this large observational study, we observed an overall
increased use of antihypertensive and lipid-lowering
drugs, and better control of risk factors between 1998 and
2004. For lipid-lowering treatment, improvements were
mainly due to an increased proportion of type 2 diabetes
patients who were initiated on drug treatment, whereas
for hypertension improvements especially concerned the
intensification of treatment in patients already on antihy-
pertensive therapy. In general, treatment initiations were
more likely in patients with related cardiovascular comor-
bidity. Otherwise, treatment changes were mainly deter-
mined by elevated levels of the corresponding risk factor.
We did not observe increased initiation rates of drug ther-
apy in patients with both hypertension and hyperlipi-
demia. We also did not observe any gender differences
regarding the initiation or intensification of drug treat-
ment.
Despite these generally favourable improvements in the
management of hyperlipidemia and hypertension, still
only one-third of patients with insufficiently controlled
blood pressure or lipid ratio levels in 2003 received an ini-
tiation or intensification of antihypertensive or lipid-low-
ering treatment in 2004. Other studies have reported
similar low rates of treatment initiations, but higher rates
of intensifications particularly for lipid-lowering therapy
[11,20,21]. In a study in an US academic medical centre
in 1997 to 1999, 30% with elevated LDL cholesterol levels
received a treatment intensification, and 30% of patients
with elevated SBP levels [21]. In a Veterans Affairs study in
1998 to 1999, 39% of patients with diabetes and elevated
Percentage of patients in subgroups stratified by lipid and  blood pressure levels initiated on lipid-lowering therapy Figure 2
Percentage of patients in subgroups stratified by lipid 
and blood pressure levels initiated on lipid-lowering 
therapy. Black bars = lipid-lowering therapy recommended 
for most patients aged 50–70; grey bars = lipid-lowering 
therapy recommended for most smoking patients and males 
aged 60–70 years; white bars = lipid-lowering therapy seldom 
recommended. SBP, systolic blood pressure; TC, total cho-
lesterol; HDL, high-density lipoprotein.
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Table 2: Multivariable analyses of factors associated with initiation and intensification of lipid-lowering and antihypertensive drug 
therapy
Lipid-lowering drug therapy Antihypertensive drug therapy
Initiation Intensification Initiation Intensification
OR*(95% CI) OR(95% CI) OR(95% CI) OR(95% CI)
Age (per 10 years) 0.7 (0.6–0.8) - 1.2 (1.1–1.3) 1.1 (1.0–1.2)
G e n d e r ----
HbA1c (%) - - 0.9 (0.8–1.0) -
Systolic blood pressure (per 10 mmHg) 1.1 (1.0–1.1) - 1.3 (1.2–1.4) 1.1 (1.1–1.2)
Diastolic blood pressure (per 10 mmHg) - - 1.2 (1.0–1.4) 1.1 (1.0–1.2)
TC/HDL ratio 1.8 (1.6–1.9) 1.3 (1.1–1.5) 1.2 (1.1–1.3) -
History of MI/AP 1.9 (1.4–2.5) - 2.3 (1.6–3.3) -
Year of screening 1.3 (1.2–1.4) 0.9 (0.8–1.0) 1.1 (1.1–1.2) 1.1(1.1–1.1)
* Additionally adjusted for body mass index. OR, odds ratio; HbA1c, haemoglobin A1c; TC, total cholesterol; HDL, high-density lipoprotein; MI, 
myocardial infarction; AP, angina pectoris.Cardiovascular Diabetology 2007, 6:25 http://www.cardiab.com/content/6/1/25
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LDL cholesterol levels received either a treatment initia-
tion or intensification [20]. More recently, a study within
a US medical care program in 2002 to 2003 showed even
higher rates of therapy initiation or intensification: 64%
of patients with insufficiently controlled SBP levels and
47% for insufficiently controlled LDL cholesterol levels
[22]. However, their study population included all
patients with hypertension, hyperlipidemia, diabetes mel-
litus or a combination of these conditions. It is known
that patients with diabetes receive less intensive antihy-
pertensive and lipid-lowering medication therapy than
patients without diabetes [14]. Also, it should be noted
that in our study, the number of patients with insuffi-
ciently controlled lipid levels was quite low in the latter
years, leaving not much room for further improvement in
this group of patients. The lack of gender differences sug-
gests that disparities in quality of care measures observed
in other countries regarding cardiovascular disease and
diabetes management may not be that distinct in The
Netherlands [23].
Several causes have been proposed why physicians may
not initiate or intensify therapy [24]. Physicians may be
reluctant to prescribe additional drugs because of con-
cerns about medicalisation and poor adherence to treat-
ment [25-27]. At the beginning of our study period, GPs
were clearly less eager to intensify antihypertensive treat-
ment in patients already receiving two or more antihyper-
tensive drugs. Secondly, there may be barriers related to
the strict high-risk approach to primary prevention.
Aggressive treatment may not be beneficial or safe for all
patients [28]. Although we used relatively lenient target
levels for both blood pressure and lipid control in our
study, some GPs may accept higher levels, especially in
patient without additional cardiovascular comorbidity. It
has also been suggested that the combined risk approach
may be difficult to implement in routine practice. The
content and format of cardiovascular risk tables have been
criticized, and risk calculator use is not common [15,16].
We indeed observed that the percentage of lipid-lowering
treatment initiations was not higher in patients with ele-
vated blood pressure levels. According to guideline rec-
ommendations, lipid-lowering therapy is indicated in
patients with high lipid ratio levels but also in patient
with lower lipid ratio levels who have hypertension.
Results of multivariable analyses showed that TC/HDL
ratio was the strongest predictor of the initiation of lipid-
lowering therapy and SBP levels only had a weak effect.
More importantly, there was no significant interaction
between TC/HDL values and SBP levels, which suggests
that the recommended combined assessment of blood
pressure and lipid levels has not yet been adopted in clin-
ical practice. Our finding that physicians primarily man-
age single risk factors is consistent with results from other
recent studies [11,29-31].
A limitation of this study is that we evaluated the manage-
ment of hyperlipidemia and hypertension within a
shared-care project. Specialist nurses performed the
annual control of type 2 diabetes patients which may have
facilitated physicians to provide better care [17]. Specialist
nurses for diabetes care are, however, common in many
health care settings. Another limitation is that the data
were collected on an annual basis. As a result we could not
assess whether physicians responded immediately to a
visit of an elevated risk factor level. Since many patients
with insufficiently controlled blood pressure or lipid ratio
levels did not receive a treatment initiation or intensifica-
tion in the following year, our results suggests that physi-
cians missed several opportunities to increase medication
regimes or dosage. An important strength of this study is
that data were collected over a long time period enabling
to assess trends in treatment initiation and intensification
over a 6-year period. The average demographic character-
istics and diabetes duration in our study population
remained stable over these years.
Conclusion
Although our study shows that the management of hyper-
tension and hyperlipidemia in patients with diabetes has
improved in the past decade, it also demonstrates specific
problems that need more attention. Physicians' readiness
to start lipid-lowering therapy in patients with diabetes
has increased but awareness for more intensive treatment
in patients with additional hypertension appears to be
lacking. In addition, the willingness to intensify antihy-
pertensive treatment in patients with elevated blood pres-
sure levels remains low. In the majority of treated patients
no further treatment changes were made, and dosages
Trends in percentages of patients with elevated blood pres- sure levels and subsequent treatment modifications (1998– 2004) Figure 3
Trends in percentages of patients with elevated blood pres-
sure levels and subsequent treatment modifications (1998–
2004).
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were seldom increased despite uncontrolled risk factor
levels.
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